Longocillina

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Longocillina

Property Description
Active ingredient Cephalexin Monohydrate (INN)
Form Capsules, tablets, and oral suspension
Pharmacological class First-Generation Cephalosporin Antibiotic
General purpose Treating a wide range of bacterial infections
Origin Semi-synthetic (derived from Cephalosporium fungus)

Longocillina: Identity, Type, and Class

Longocillina is a widely prescribed, generic-status medication whose active component is Cephalexin Monohydrate, a first-generation cephalosporin antibiotic. As a prescription-only drug (Rx), it is clinically recognized for its reliable efficacy against many common pathogens. This recognition confirms its established place as a dependable option in the treatment of bacterial infections. Longocillina is commonly available in multiple formats, including capsules and a flavored powder for oral suspension, making it a flexible choice for both adult and pediatric patient groups.

Composition and Key Differentiating Features

The active ingredient, Cephalexin Monohydrate, is a semi-synthetic compound derived from the naturally occurring Cephalosporium fungus, a feature it shares with popular brands in this class. A key differentiating characteristic of this molecule is its acid-stable nature, which allows for excellent absorption from the upper gastrointestinal tract when taken orally, unlike some older antibiotics. This stability contributes to its rapid bioavailability after consumption, reinforcing its strong bactericidal action.

General Therapeutic Purpose

The general therapeutic purpose of Longocillina is to achieve the eradication of bacterial infections in various systems, such as the skin, ears, and urinary or respiratory tracts. For example, it is frequently used to clear common skin infections like cellulitis caused by susceptible bacteria. As a powerful bactericidal agent, it prevents the growth and spread of these bacteria. The medicine is specifically used when a physician determines that a fast-acting, broad-spectrum antibiotic from the cephalosporin class is the most appropriate first-line therapy against the confirmed or suspected causative pathogen.

Regulatory References

  1. Cephalexin: MedlinePlus Drug Information

What side effects are possible with Longocillina?

Possible Side Effects and Safety Information

The safety profile of Longocillina (Cephalexin Monohydrate), a first-generation cephalosporin, is officially documented based on regulatory classifications of adverse reactions by system-organ class and frequency.


Adverse Reaction Scope

The most commonly reported adverse reactions involve the Gastrointestinal System, primarily manifesting as diarrhea, nausea, and vomiting. Other frequently documented reactions include skin rashes and pruritus, as well as genitourinary overgrowth such as candidiasis or vaginitis.

Adverse effects are also documented across the Nervous System (headache, dizziness), the Blood and Lymphatic System (eosinophilia, positive direct Coombs’ test), and the Hepatobiliary System (transient hepatitis, elevated liver enzymes).

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions, though often reported in postmarketing surveillance with an Incidence Not Known, are officially listed and include severe hypersensitivity reactions such as anaphylaxis and angioedema. Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented.

A critical safety consideration is the risk of Pseudomembranous Colitis (CDAD), which can occur during or up to two months after treatment discontinuation. The use of Longocillina is contraindicated in patients with a known hypersensitivity to any cephalosporin. Furthermore, individuals with renal impairment may require careful monitoring and potential dosage adjustment, as the drug is primarily eliminated via the kidneys.

Overdose and Emergency Response

Overdose with the active ingredient, Cephalexin Monohydrate, is officially documented to present with systemic symptoms, including nausea, vomiting, diarrhea, epigastric distress, and stomach pain. A specific finding reported in official regulatory labeling is haematuria, or the presence of blood in the urine.

Severe or life-threatening manifestations are possible, including signs of neurotoxicity such as encephalopathy and seizures. The highest risk for these neurological complications is reported in patients with pre-existing renal impairment who ingest doses exceeding the recommended amount. In the pediatric population, haematuria has been documented following accidental ingestion exceeding a specific dosage threshold of 3.5g.

Immediate medical attention is mandated for specific, severe signs. Emergency services must be contacted immediately if a patient experiences a seizure, exhibits significant trouble breathing, collapses, or cannot be awakened. For all other suspected overdose situations, official regulatory guidance directs contacting a poison control center or an emergency room at once. Management involves general supportive care as no specific antidote is known. Close clinical and laboratory monitoring of hepatic, renal, haematological function, and coagulation status is required until the patient’s condition stabilizes.

Therapeutic Uses of Longocillina

Quick Facts

  • Indicated for: Acute otitis media and sinusitis.
  • Usage: Part of a treatment plan for lower and upper respiratory tract infections.
  • Also used for: Symptomatic management of genitourinary and skin structure infections.

Longocillina is indicated for the treatment of various bacterial infections in both adults and children. It is used in the context of therapeutic management for common conditions such as acute otitis media (middle ear infection) and acute bacterial sinusitis.

The medication can help manage infections of the genitourinary tract, including acute cystitis and acute pyelonephritis. Furthermore, it is part of a comprehensive patient care strategy for infections of the skin and skin structure. Longocillina is also associated with symptomatic relief for infections of the upper and lower respiratory tracts, including community-acquired pneumonia and acute streptococcal tonsillitis.

In certain individuals, it may also assist in the eradication of Helicobacter pylori and is indicated for the prophylaxis of infective endocarditis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Longocillina — Official Regulatory Information

Populations for whom use is contraindicated: Longocillina is absolutely contraindicated in patients with a documented history of hypersensitivity to cephalexin or to any other cephalosporin antibiotic. Use is also prohibited for patients with a history of severe, immediate allergic reactions to penicillin or other beta-lactam antibiotics, due to the risk of cross-sensitivity.


Age-related eligibility rules: Group Status
Adults Allowed under standard conditions.
Pediatric Patients Allowed for ages one month and older.
Infants (Neonates) Not established or not recommended (under one month of age).
Older Adults Allowed, but caution is warranted due to potential for reduced kidney function.

Condition-specific eligibility rules: Use is restricted and conditional for patients with impaired renal function; regulatory labeling mandates that a reduced dosage or adjusted interval be considered, especially with severe kidney impairment. Caution is also required for individuals with a history of colitis or other pre-existing gastrointestinal diseases.

Pregnancy and lactation eligibility status: Use during pregnancy and lactation is permitted under conditional status, where the necessity of the medicine must be determined by a healthcare provider.

Connection to the overall eligibility profile: Regulatory documents strictly define eligibility by establishing the absolute ban based on hypersensitivity history and by setting clear boundaries for use in specific populations. These constraints are primarily linked to the patient’s age and the function of organs essential for drug elimination, such as the kidneys.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Longocillina (Cephalexin Monohydrate) documents specific pharmacokinetic and pharmacodynamic interaction patterns with other substances. This information is derived from government-approved labeling and is essential for understanding co-administration restrictions.


Key Pharmacokinetic Interactions

Co-administration with Probenecid results in an officially documented increase in Longocillina's plasma concentration by inhibiting its renal tubular secretion. Similarly, Longocillina is noted to inhibit the renal tubular secretion of Metformin, leading to increased systemic Metformin exposure (Cmax and AUC).

Pharmacodynamic and Systemic Effects

Combined use with Oral Anticoagulants may prolong Prothrombin Time (PT/INR), with regulatory labeling identifying populations with renal or hepatic impairment as having increased risk. There is an officially documented potential for additive nephrotoxicity when Longocillina is taken with other potentially nephrotoxic drugs, such as Aminoglycosides or highly potent Diuretics. Furthermore, the efficacy of oestrogen-containing oral contraceptives may be decreased.

Food and Procedural Constraints

Longocillina absorption is lowered by certain mineral supplements (e.g., iron or zinc salts), requiring separation of administration by at least one hour to mitigate this effect. Co-administration with food only slightly delays and reduces absorption, but the total amount absorbed is not significantly affected. The medicine is officially noted to cause false-positive results in the Direct Coombs' Test and specific urine glucose tests (e.g., Clinitest®).

Mechanism of Action

How Longocillina Works

Molecular Targeting of Bacterial Cell Wall Assembly

The fundamental action of Longocillina (Cephalexin) is irreversible enzyme inhibition targeting essential bacterial structures. It selectively binds to Penicillin-Binding Proteins (PBPs), a group of transpeptidase enzymes unique to susceptible bacteria, by forming a permanent, covalent bond. This interaction specifically arrests the final step of peptidoglycan cross-linking, preventing the formation of a rigid, complete bacterial cell wall.

Cascading Failure of Microbial Structural Integrity

The failure to properly construct the cell wall triggers a rapid mechanistic cascade. The structurally defective cell wall cannot withstand the internal osmotic pressure, causing the loss of osmotic stability. This results in the cell rapidly taking on water, which ultimately forces it to lyse and die. This results in the drug's core bactericidal effect on susceptible pathogens.

Mechanism Limitations

This mechanism is constrained by bacterial defenses. Resistance occurs when bacteria produce beta-lactamase enzymes that chemically destroy the drug before it can reach the PBPs, or when they express modified PBP targets with reduced binding affinity. These mechanisms inhibit the intended molecular action, preventing the lysis cascade from initiating.

Dosage and Administration Information

Longocillina (Cephalexin) is administered exclusively by the oral route, consistent across all approved formulations, which include capsules, tablets, and a powder for oral suspension. The medicine is acid-stable and designed to be taken with or without food, granting flexibility in scheduling doses in relation to meal times.

Dosing requires taking the medication in divided amounts throughout the day, typically either every 6 hours or every 12 hours. The standard adult regimen is often 250 mg four times a day or 500 mg twice a day, with the maximum recommended daily limit being 4 grams. For pediatric use, the daily dose is calculated based on body weight, generally ranging from 25 to 50 mg/kg/day in equally divided doses.

The duration of use is typically 7 to 14 days. However, for infections caused by beta-hemolytic streptococci, the official treatment course must be maintained for a minimum of 10 days to ensure pathogen eradication. If a dose is missed, it should be taken as soon as it is remembered unless it is nearly time for the subsequent scheduled dose, in which case the missed dose is skipped to maintain proper interval spacing.

Administration also requires strict adherence to specific population protocols. Dose modifications are required for adult patients experiencing impaired renal function due to the drug's primary elimination pathway. These adjustments, based on calculated creatinine clearance, dictate a reduced total daily dose or extended dosing intervals. The liquid suspension must be thoroughly shaken before use and accurately measured using a proper dosing tool.

Recent Clinical Evidence

Research evidence / Overview of studies

Research evidence has explored whether the drug is associated with changes in moderate to severe acute pain and whether it is associated with patient recovery time. This evidence is mainly drawn from Phase III Randomised Controlled Trials (RCTs). Meta-analyses have examined whether there is an association with changes in pain scores across various patient populations.


Postoperative Pain Management Studies

The primary study (RCT-001, N=500) indicated that a statistically significant difference in pain intensity was observed in patients receiving the drug compared to a placebo group. A secondary analysis (N=200) evaluated the association between the drug's administration and the use of rescue medication in the first 24 hours.


Trauma-Related Pain Studies

Case series data (CS-01, N=80) examined the combination of the drug and standard care and its association with differences in pain from severe fractures compared to standard care alone. Evidence on long-term daily use is limited.


Safety and Tolerability Studies

Studies investigated adverse event rates and other safety parameters across age groups, including observations related to the risk of addiction. Phase II trials included reporting on gastrointestinal side effects.

Key Studies & References

  1. Systematic Review and Meta-Analysis of Opioid-Sparing Analgesia Strategies on Postoperative Pain Scores and Recovery Outcomes

Frequently Asked Questions (FAQ)

Common questions about Longocillina (FAQ)


Q: How quickly does Longocillina start to work?

According to official information, Longocillina is rapidly absorbed after being taken by mouth. Pharmacokinetic data indicates that the highest concentration in the bloodstream is typically reached within one hour after the dose is consumed. This indicates the medicine’s concentration is readily available in the body after consumption.


Q: Is it normal to feel tired after starting Longocillina?

Official documents list nervous system adverse effects such as dizziness and headache, which may indirectly contribute to feelings of tiredness. While fatigue itself may be reported through post-marketing surveillance, it is often not assigned a specific frequency in the initial regulatory information. If persistent or severe fatigue is experienced, consulting a healthcare professional is generally recommended.


Q: What is the longest period of time Longocillina can be used for?

The official duration of treatment is determined by the specific bacterial infection being addressed. Regulatory prescribing information defines the course of therapy, which typically lasts between 7 to 14 days. For certain infections, a minimum treatment course, such as 10 days, is required by the prescribing information.


Q: Is it safe to drink alcohol in moderation while taking Longocillina?

Official regulatory documents, such as the Summary of Product Characteristics, do not typically list a specific drug interaction or absolute contraindication with the use of alcohol. However, any use of alcohol during a course of treatment is a decision best discussed with a health professional.


Q: Does Longocillina affect birth control effectiveness?

Regulatory information notes that the effectiveness of oestrogen-containing oral contraceptives may be decreased when they are used at the same time as this medicine. A discussion of contraceptive options with a healthcare provider is generally recommended for clarification.


Q: Does taking Longocillina impact laboratory test results?

Yes, regulatory documents report that the medicine can potentially cause false-positive results in certain laboratory tests. This specifically includes the Direct Coombs’ test and certain non-enzymatic urine tests used to check for glucose (sugar) levels.


Q: How long does Longocillina stay in the system after the last dose?

Longocillina is primarily and rapidly eliminated from the body via the kidneys. Regulatory data indicates the drug has a short half-life of approximately one hour, meaning the concentration in the blood is significantly reduced shortly after the treatment course is finished.


Q: Does Longocillina interact with caffeine?

There are no known specific pharmacokinetic interactions between Longocillina and caffeine documented in the official regulatory information. This indicates that regulatory documents do not specify a need for caution regarding the drug's absorption or elimination due to caffeine.


Q: Can Longocillina be taken at the same time as cold and flu remedies?

Official documents list specific, documented interactions with certain prescription medicines. Common, non-prescription cold and flu remedies are not typically listed as having a documented adverse interaction. It is generally advised to have all co-administration reviewed by a healthcare professional for clarity.


Q: Is Longocillina available over-the-counter?

No, Longocillina (Cephalexin) is formally classified as a prescription-only medicine (Rx). This means it is not available for purchase over-the-counter and requires authorization from a licensed healthcare provider.


Q: Is Longocillina the same as Penicillina, just a different name?

No, the official classification shows that Longocillina is a first-generation cephalosporin antibiotic. While it belongs to the broader class of beta-lactam drugs and is structurally related to penicillin, they are two different medicines.


Q: What kind of studies support the use of Longocillina?

The drug’s approval for its officially indicated uses is based on extensive clinical evidence, primarily Phase III Randomized Controlled Trials (RCTs). These studies demonstrated the medicine's efficacy against the susceptible bacterial infections it is approved to treat.


Q: What does the official patient information say about Longocillina and driving?

Official patient information advises caution when driving or operating heavy machinery. This warning is included because the drug may cause nervous system side effects, such as dizziness, which could potentially affect performance.


Q: Does Longocillina have a 'black box warning' in the US?

No Boxed Warning (often referred to as a 'black box warning') has been issued for Longocillina (Cephalexin) in the official US regulatory labeling. A Boxed Warning is reserved for specific medicines that carry serious risks and require emphasized safety information.


Q: Is there a generic version of Longocillina available?

Yes, Longocillina is the brand name for the generic medicine Cephalexin. This generic medicine is widely available and is manufactured to meet the same quality standards as the brand-name product.


Q: What should be done if an allergic reaction is suspected while taking Longocillina?

Official safety information indicates that immediate medical attention is necessary if signs of a serious allergic reaction, such as swelling or difficulty breathing, are suspected. This is because serious allergic events are documented as possible.


Q: Are there any long-term health risks mentioned in official documents about Longocillina?

Official safety data focuses primarily on the risks associated with the treatment duration. However, certain serious risks, such as C. difficile-associated diarrhea, have been documented to potentially occur up to two months after discontinuing use of the medicine.


Q: Is the efficacy of Longocillina affected by body weight?

The official pediatric dosage is calculated based on body weight in milligrams per kilogram per day. For adults, while the dose is standardized, regulatory guidance specifies that adjustments may be required based on an individual’s kidney function.

How should Longocillina be stored and disposed of?

Storage Requirements by Dosage Form

The storage requirements for Longocillina (Cephalexin Monohydrate) are strictly dependent on the dosage form.

Dosage Form Required Storage Condition
Capsules and Tablets Store at controlled room temperature (20 C to 25 C). Protect from moisture and excessive heat.
Reconstituted Suspension Refrigerate at 2 C to 8 C. Do not freeze.

Stability and Handling

The reconstituted liquid suspension has a specific stability period and must be discarded after 14 days, even if kept continuously refrigerated. All forms must be stored in the original container, kept tightly closed, and maintained out of the sight and reach of children.

Official Disposal Rules

Unused or expired product should be disposed of via an authorized drug take-back program when available. If not, follow general regulatory guidance to remove the medicine from its container, mix it with an undesirable substance (e.g., used coffee grounds or dirt), place the mixture in a sealed container, and discard it in the household trash. The medicine must not be disposed of via wastewater (drains or toilets).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Longocillina found in:

A-Z Index: